Published in Clin Chem on December 18, 2009
Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods (2012) 4.93
PASSEL: the PeptideAtlas SRMexperiment library. Proteomics (2012) 3.14
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol (2011) 2.44
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin Chem (2010) 2.11
Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods (2013) 2.04
Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics (2012) 2.04
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods (2013) 1.54
Protein significance analysis in selected reaction monitoring (SRM) measurements. Mol Cell Proteomics (2011) 1.45
Panorama: a targeted proteomics knowledge base. J Proteome Res (2014) 1.43
Generating and navigating proteome maps using mass spectrometry. Nat Rev Mol Cell Biol (2010) 1.29
ATAQS: A computational software tool for high throughput transition optimization and validation for selected reaction monitoring mass spectrometry. BMC Bioinformatics (2011) 1.28
Radiation metabolomics and its potential in biodosimetry. Int J Radiat Biol (2011) 1.20
Computational mass spectrometry-based proteomics. PLoS Comput Biol (2011) 1.18
Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics. BMC Bioinformatics (2012) 1.18
Accurate peptide fragment mass analysis: multiplexed peptide identification and quantification. J Proteome Res (2012) 1.10
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. Clin Chem (2016) 1.10
Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol Cell Proteomics (2015) 1.02
Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics (2014) 1.02
Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS). Mol Cell Proteomics (2013) 1.01
File formats commonly used in mass spectrometry proteomics. Mol Cell Proteomics (2012) 1.01
A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues. Mol Cell Proteomics (2014) 1.00
Open source libraries and frameworks for mass spectrometry based proteomics: a developer's perspective. Biochim Biophys Acta (2013) 1.00
Automated selected reaction monitoring software for accurate label-free protein quantification. J Proteome Res (2012) 0.99
Reproducible and consistent quantification of the Saccharomyces cerevisiae proteome by SWATH-mass spectrometry. Mol Cell Proteomics (2015) 0.96
Applications of selected reaction monitoring (SRM)-mass spectrometry (MS) for quantitative measurement of signaling pathways. Methods (2013) 0.94
Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles). Mol Cell Proteomics (2011) 0.94
Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. J Proteome Res (2013) 0.93
An assessment of current bioinformatic solutions for analyzing LC-MS data acquired by selected reaction monitoring technology. Proteomics (2012) 0.92
Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles). J Proteome Res (2011) 0.91
From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry. Clin Chem (2014) 0.91
Review of software tools for design and analysis of large scale MRM proteomic datasets. Methods (2013) 0.90
Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. Anal Chem (2015) 0.88
Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brain tissue. Mol Cell Proteomics (2012) 0.87
Synthetic peptide arrays for pathway-level protein monitoring by liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics (2010) 0.87
Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. J Proteome Res (2013) 0.86
The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med (2014) 0.84
Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLoS One (2014) 0.84
18O-labeled proteome reference as global internal standards for targeted quantification by selected reaction monitoring-mass spectrometry. Mol Cell Proteomics (2011) 0.83
Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. Bioanalysis (2012) 0.83
Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels. J Clin Bioinforma (2011) 0.82
Detection and correction of interference in SRM analysis. Methods (2013) 0.81
Neucode Labels for Multiplexed, Absolute Protein Quantification. Anal Chem (2016) 0.81
Analysis of naphthalene adduct binding sites in model proteins by tandem mass spectrometry. Chem Biol Interact (2012) 0.79
A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer (2015) 0.79
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med (2014) 0.79
Novel approaches for the identification of biomarkers of aggressive prostate cancer. Genome Med (2013) 0.78
Secretome profiling of Cryptococcus neoformans reveals regulation of a subset of virulence-associated proteins and potential biomarkers by protein kinase A. BMC Microbiol (2015) 0.78
Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry. Sci Rep (2015) 0.77
Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry. Int J Mol Sci (2015) 0.77
Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy. Mol Cell Proteomics (2014) 0.76
Simultaneous Proteomic Discovery and Targeted Monitoring using Liquid Chromatography, Ion Mobility Spectrometry, and Mass Spectrometry. Mol Cell Proteomics (2016) 0.75
Quantitative LC-MS/MS Analysis of Proteins Involved in Metastasis of Breast Cancer. PLoS One (2015) 0.75
Transitioning from Targeted to Comprehensive Mass Spectrometry Using Genetic Algorithms. J Am Soc Mass Spectrom (2016) 0.75
Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain. Methods Mol Biol (2017) 0.75
Study of Isobaric Interference in Quantification of Citrulline by Parallel Fragmentation Monitoring. Mass Spectrom (Tokyo) (2014) 0.75
Towards reproducible MRM based biomarker discovery using dried blood spots. Sci Rep (2017) 0.75
Data Pre-Processing for Label-Free Multiple Reaction Monitoring (MRM) Experiments. Biology (Basel) (2014) 0.75
Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease. Proteomics (2016) 0.75
Ranking Fragment Ions Based on Outlier Detection for Improved Label-Free Quantification in Data-Independent Acquisition LC-MS/MS. J Proteome Res (2015) 0.75
ROCR: visualizing classifier performance in R. Bioinformatics (2005) 19.60
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A (2003) 10.82
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell (2009) 6.54
Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol (2008) 6.38
Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem (1999) 5.03
Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem (1996) 3.97
Expediting the development of targeted SRM assays: using data from shotgun proteomics to automate method development. J Proteome Res (2009) 3.44
MRMer, an interactive open source and cross-platform system for data extraction and visualization of multiple reaction monitoring experiments. Mol Cell Proteomics (2008) 2.89
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem (2006) 2.55
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics (2008) 2.11
LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem (2007) 2.09
Mechanistic investigation of ionization suppression in electrospray ionization. J Am Soc Mass Spectrom (2000) 2.05
Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal Chem (1998) 1.90
De novo sequencing, peptide composition analysis, and composition-based sequencing: a new strategy employing accurate mass determination by fourier transform ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom (2004) 1.52
Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation. Anal Chem (1979) 1.41
Assessing analytical specificity in quantitative analysis using tandem mass spectrometry. Clin Biochem (2005) 1.31
Improved validation of peptide MS/MS assignments using spectral intensity prediction. Mol Cell Proteomics (2006) 1.28
Comprehensive screening of urine samples for inborn errors of metabolism by electrospray tandem mass spectrometry. Clin Chem (2002) 1.10
Unique ion signature mass spectrometry, a deterministic method to assign peptide identity. Mol Cell Proteomics (2009) 1.08
Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry. Anal Chem (2009) 1.07
Noninvasive human metabolome analysis for differential diagnosis of inborn errors of metabolism. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.03
Isobaric metabolite interferences and the requirement for close examination of raw data in addition to stringent chromatographic separations in liquid chromatography/tandem mass spectrometric analysis of drugs in biological matrix. Rapid Commun Mass Spectrom (2008) 0.95
High accuracy determination of calcium in blood serum by isotope dilution mass spectrometry. Anal Chem (1972) 0.95
Use of mass spectrometry for confirmation of animal drug residues. J Assoc Off Anal Chem (1978) 0.90
Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients. J Proteomics (2007) 0.88
On the risk of false positive identification using multiple ion monitoring in qualitative mass spectrometry: large-scale intercomparisons with a comprehensive mass spectral library. J Am Soc Mass Spectrom (2006) 0.88
Quantitation of anabolic hormones and their metabolites in bovine serum and urine by liquid chromatography-tandem mass spectrometry. J Chromatogr A (2000) 0.86
Stable isotopes in the management and diagnosis of inborn errors of metabolism. Can J Physiol Pharmacol (1990) 0.85
Determination of sulfonic acid degradates of chloroacetanilide and chloroacetamide herbicides in groundwater by LC/MS/MS. Anal Chem (1998) 0.85
Stable isotopes in pharmacology studies: present and future. J Clin Pharmacol (1986) 0.83
Total serum cholesterol by isotope dilution/mass spectrometry: a candidate definitive method. Clin Chem (1980) 0.82
Establishing the fitness for purpose of mass spectrometric methods. J Am Soc Mass Spectrom (2003) 0.82
Regulatory mass spectrometry. Biomed Mass Spectrom (1981) 0.81
On-line computer controlled multiple ion detection in combined gas chromatography-mass spectrometry. Anal Chem (1973) 0.80
Implications of matrix effects in ultra-fast gradient or fast isocratic liquid chromatography with mass spectrometry in drug discovery. Rapid Commun Mass Spectrom (2002) 0.79
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
A mitochondrial protein compendium elucidates complex I disease biology. Cell (2008) 13.51
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet (2006) 4.67
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res (2008) 3.36
Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest (2011) 3.23
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A (2009) 2.94
A human proteome detection and quantitation project. Mol Cell Proteomics (2009) 2.80
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J (2007) 2.48
Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest (2008) 2.46
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol (2011) 2.44
The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics (2011) 2.43
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
EMRE is an essential component of the mitochondrial calcium uniporter complex. Science (2013) 2.39
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell (2013) 2.35
Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol (2009) 2.27
Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods (2013) 2.22
Phosphorylation by cyclin B-Cdk underlies release of mitotic exit activator Cdc14 from the nucleolus. Science (2004) 2.14
Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics (2008) 2.11
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods (2013) 2.04
Metabolic signatures of exercise in human plasma. Sci Transl Med (2010) 1.99
A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol (2010) 1.90
PEPPeR, a platform for experimental proteomic pattern recognition. Mol Cell Proteomics (2006) 1.90
Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. Anal Chem (2010) 1.86
Systematic discovery of TLR signaling components delineates viral-sensing circuits. Cell (2011) 1.83
DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell (2010) 1.78
Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics (2011) 1.71
Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem (2008) 1.66
ZBED6, a novel transcription factor derived from a domesticated DNA transposon regulates IGF2 expression and muscle growth. PLoS Biol (2009) 1.61
Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol Cell Proteomics (2012) 1.58
Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics (2011) 1.52
Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics (2012) 1.48
Identification of apolipoprotein D as a cardioprotective gene using a mouse model of lethal atherosclerotic coronary artery disease. Proc Natl Acad Sci U S A (2013) 1.48
Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics (2011) 1.44
Panorama: a targeted proteomics knowledge base. J Proteome Res (2014) 1.43
Large-scale identification of ubiquitination sites by mass spectrometry. Nat Protoc (2013) 1.41
H2A.Z landscapes and dual modifications in pluripotent and multipotent stem cells underlie complex genome regulatory functions. Genome Biol (2012) 1.33
Place of pattern in proteomic biomarker discovery. J Proteome Res (2005) 1.32
TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin. Oncogene (2004) 1.30
Quantitative assessment of chromatin immunoprecipitation grade antibodies directed against histone modifications reveals patterns of co-occurring marks on histone protein molecules. Mol Cell Proteomics (2012) 1.27
Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell (2012) 1.26
Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer (2014) 1.23
Empirical Bayes analysis of quantitative proteomics experiments. PLoS One (2009) 1.21
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov (2013) 1.20
Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res (2013) 1.20
Directed sample interrogation utilizing an accurate mass exclusion-based data-dependent acquisition strategy (AMEx). J Proteome Res (2009) 1.18
Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics. BMC Bioinformatics (2012) 1.18
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. Elife (2014) 1.16
Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res (2010) 1.15
Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. Cell Metab (2011) 1.14
N-Terminal peptide labeling strategy for incorporation of isotopic tags: a method for the determination of site-specific absolute phosphorylation stoichiometry. Rapid Commun Mass Spectrom (2002) 1.13
Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem (2009) 1.10
Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem (2009) 1.07
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A (2012) 1.06
Integration of proteomic-based tools for improved biomarkers of myocardial injury. Clin Chem (2009) 1.05
Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop. Biochem Biophys Res Commun (2006) 1.05
Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res (2011) 1.04
Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway. PLoS One (2011) 1.04
Mass spectrometry-based methods for phosphorylation site mapping of hyperphosphorylated proteins applied to Net1, a regulator of exit from mitosis in yeast. Mol Cell Proteomics (2002) 1.04